You are here

Pipeline Discoveries for Autoimmune Diseases and Chronic Inflammation

Pfizer's mission is to deliver medicines that make a real difference in quality of life for patients with autoimmune diseases and chronic inflammation. Scientists in our research and development (R&D) programs are committed to speeding the delivery of new treatments. We pledge to maintain the safety of patients who take part in our trials and to uphold the highest ethical standards in all of our research initiatives.

365体育足球On this page, you will find more information about our pipeline, which investigational therapies are under development, and in which stages.

 

Inflammation Immunology Pipeline & Trials

Immunology Pipeline as of January 28, 2020

  • Discovery Projects
  • Phase 1
    3
  • Phase 2
    16
  • Phase 3
    3
  • Registration
    2
  • Total24
 
Compound Name
Indication
Phase
Submission Type
Compound Type
PF-06835375
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
chemokine inhibitor
Go to clinical trial
Lupus (Biologic) Phase 1 New Molecular Entity Biologic
Dekavil
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 2
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
IL-10
Go to clinical trial
Rheumatoid Arthritis (Biologic) Phase 2 New Molecular Entity Biologic
Dekavil
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 2
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
IL-10
Go to clinical trial
Ulcerative Colitis (Biologic) Phase 2 Product Enhancement Biologic
PF-06823859
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 2
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
interferon, beta 1, fibroblast (IFNB1) Blocker
Go to clinical trial
Inflammatory Disorders (Biologic) Phase 2 New Molecular Entity Biologic
PF-06650833
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
IRAK4
Go to clinical trial
Rheumatoid Arthritis Phase 2 New Molecular Entity Small Molecule
PF-06650833 / PF-06700841 / PF-06826647
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
IRAK4; TYK2/JAK1; TYK2 Inhibitor
Go to clinical trial
Hidradenitis Suppurativa
Project advanced
Phase 2 Product Enhancement Small Molecule
Xeljanz (tofacitinib)
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
JAK Inhibitor
Ankylosing Spondylitis Phase 3 Product Enhancement Small Molecule
abrocitinib (PF-04965842)
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
JAK Inhibitor
Atopic Dermatitis (BREAKTHROUGH) Phase 3 New Molecular Entity Small Molecule
PF-06651600
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
JAK3/TEC
Alopecia Areata (BREAKTHROUGH) Phase 3 New Molecular Entity Small Molecule
PF-06651600
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
JAK3/TEC
Go to clinical trial
Rheumatoid Arthritis Phase 2 Product Enhancement Small Molecule
PF-06651600 / PF-06700841
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
JAK3/TEC; TYK2/JAK1
Go to clinical trial
Ulcerative Colitis Phase 2 New Molecular Entity Small Molecule
PF-06651600 / PF-06700841
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
JAK3/TEC; TYK2/JAK1
Go to clinical trial
Crohn's Disease Phase 2 Product Enhancement Small Molecule
PF-06651600 / PF-06700841
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
JAK3/TEC; TYK2/JAK1
Go to clinical trial
Vitiligo Phase 2 Product Enhancement Small Molecule
crisaborole (PF-06940799)
Therapeutic Area:
Inflammation & Immunology
Phase:Registration
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
PDE4 Inhibitor
Go to clinical trial
Atopic Dermatitis (E.U.) Registration New Molecular Entity Small Molecule
PF-06480605
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 2
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
TNFSF15 Blocker
Go to clinical trial
Ulcerative Colitis (Biologic) Phase 2 New Molecular Entity Biologic
PF-07038124
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
Topical PDE4 Inhibitor
Go to clinical trial
Atopic Dermatitis
Project advanced
Phase 1 New Molecular Entity Small Molecule
PF-06700841
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
Topical TYK2/JAK1
Go to clinical trial
Atopic Dermatitis Phase 2 New Molecular Entity Small Molecule
PF-06700841
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
Topical TYK2/JAK1
Go to clinical trial
Psoriasis Phase 2 New Molecular Entity Small Molecule
Select one or more conditions listed below. You can also enter your location (city, state, and/or Zip code) to find a trial near you.Clear Options